Prelude Therapeutics (PRLD) Free Cash Flow Growth (1y) (2020 - 2026)
Prelude Therapeutics (PRLD) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 137.65% |
| 10 | Prelude Therapeutics | 325.13 Mn | 180.53 Mn | - | 36.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.74% |
| Dec 31, 2025 | 215.35% |
| Sep 30, 2025 | 30.13% |
| Jun 30, 2025 | -11.44% |
| Mar 31, 2025 | -6.85% |
| Dec 31, 2024 | 18.88% |
| Sep 30, 2024 | -4.13% |
| Jun 30, 2024 | 18.27% |
| Mar 31, 2024 | -3.67% |
| Dec 31, 2023 | -8.87% |
| Sep 30, 2023 | -37.91% |
| Jun 30, 2023 | -44.53% |
| Mar 31, 2023 | -39.08% |
| Dec 31, 2022 | 7.30% |
| Sep 30, 2022 | 18.63% |
| Jun 30, 2022 | -2.65% |
| Mar 31, 2022 | -29.89% |
| Dec 31, 2021 | -59.80% |
| Sep 30, 2021 | -84.70% |
| Jun 30, 2021 | -114.79% |